Farnault B, Moureau-Zabotto L, de Chaisemartin C, Esterni B, Lelong B, Viret F, Giovannini M, Monges G, Delpero J-R, Bories E, Turrini O, Viens P, Resbeut M
Département de radiothérapie, institut Paoli-Calmettes, 232, boulevard Sainte-Marguerite, 13009 Marseille, France.
Cancer Radiother. 2011 Jul;15(4):279-86. doi: 10.1016/j.canrad.2011.01.005. Epub 2011 Apr 22.
Neoadjuvant chemoradiation followed by surgery is the standard of care for locally advanced rectal cancer. The aim of this study was to correlate tumour response to survival and to identify predictive factors for tumour response after chemoradiation.
From 1998 to 2008, 168 patients with histologically-proven locally advanced adenocarcinoma treated by preoperative chemoradiation before total mesorectal excision were retrospectively studied. They received a radiation dose of 45 Gy with a concomitant 5-fluoro-uracil-based chemotherapy. Analysis of tumour response was based on the lowering of T stage between pre-treatment endorectal ultrasound and pathologic specimens. Overall and progression-free survival was correlated with tumour response. Tumour response was analysed with predictive factors.
The median follow-up was 34 months. Five-year disease-free survival and overall survival were respectively of 44.4% and 74.5% in the whole population, 83.4% and 83.4% in patients with pathological complete response, 38.6% and 71.9% in patients with tumour downstaging, 29.1% and 58.9% in patients with absence of response. A pre-treatment concentration of carcinoembryonnic antigen below 5 ng/mL was significantly associated with tumour downstaging and significantly independently associated with pathologic complete tumour response (P = 0.019).
Downstaging and complete response after chemoradiation improved progression-free survival and overall survival of locally advanced rectal adenocarcinoma. In multivariate analysis, a pre-treatment concentration of carcinoembryonnic antigen below 5 ng/mL was associated with complete tumour response, hence with tumour downstaging.
新辅助放化疗后手术是局部晚期直肠癌的标准治疗方案。本研究旨在关联肿瘤反应与生存率,并确定放化疗后肿瘤反应的预测因素。
回顾性研究1998年至2008年间168例经组织学证实为局部晚期腺癌且在全直肠系膜切除术前接受术前放化疗的患者。他们接受了45 Gy的放射剂量,并同时进行基于5-氟尿嘧啶的化疗。肿瘤反应分析基于治疗前直肠内超声与病理标本之间T分期的降低情况。总生存和无进展生存与肿瘤反应相关联。对肿瘤反应与预测因素进行分析。
中位随访时间为34个月。全组患者的5年无病生存率和总生存率分别为44.4%和74.5%;病理完全缓解患者分别为83.4%和83.4%;肿瘤降期患者分别为38.6%和71.9%;无反应患者分别为29.1%和58.9%。治疗前癌胚抗原浓度低于5 ng/mL与肿瘤降期显著相关,且与病理完全肿瘤反应显著独立相关(P = 0.019)。
放化疗后的降期和完全缓解改善了局部晚期直肠腺癌的无进展生存和总生存。在多变量分析中,治疗前癌胚抗原浓度低于5 ng/mL与完全肿瘤反应相关,因此与肿瘤降期相关。